Mark Anthony McCamish
CIK 1390798 · President and CEO · last filed 2026-02-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$267.4K
Companies
6
Total Filings
38
Lifetime Open-Market Net
-$5.36M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AVADEL PHARMACEUTICALS PLC (AVDL) Delisted | Director | 0 | $21.64 | $0 | -$537.1K | 13 | 2026-02-12 |
| RFL | Director | 60,241 | $2.10 | $126.5K | $0 | 3 | 2024-01-08 |
| Vincerx Pharma, Inc. (VINCW) Delisted | Director | — | $1.61 | — | $0 | 1 | 2020-12-28 |
| Forty Seven, Inc. (FTSV) Delisted | President and CEO | 0 | — | — | -$4.82M | 12 | 2020-04-07 |
| FACT | Sr. VP & Chief Medical Officer | 13,200 | $10.67 | $140.8K | $0 | 3 | 2009-04-06 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | SVP & CMO | 14,924 | — | — | $0 | 4 | 2008-12-19 |
Recent Filings · Page 2 of 4
38 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-01-05 | RFL | Grant (A) | +27,174 | $50.0K | EDGAR |
| 2022-08-05 | AVADEL PHARMACEUTICALS PLC (AVDL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-01-05 | RFL | Grant (A) | +5,412 | $29.2K | EDGAR |
| 2021-08-05 | AVADEL PHARMACEUTICALS PLC (AVDL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-12-28 | Vincerx Pharma, Inc. (VINCW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-09-18 | AVADEL PHARMACEUTICALS PLC (AVDL) Delisted | Buy (P) | +171,000 | $985.2K | EDGAR |
| 2020-09-14 | AVADEL PHARMACEUTICALS PLC (AVDL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-08-11 | AVADEL PHARMACEUTICALS PLC (AVDL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-04-07 | Forty Seven, Inc. (FTSV) Delisted | Disp (D) | −4,595 | $0 | EDGAR |
| 2020-04-03 | Forty Seven, Inc. (FTSV) Delisted | Mixed | −63,059 | -$2.96M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.